Presentation is loading. Please wait.

Presentation is loading. Please wait.

Assessment of infarct size by biomarker measurement.

Published byErika Molenaar Modified over 5 years ago

Similar presentations

Presentation on theme: "Assessment of infarct size by biomarker measurement."— Presentation transcript:

1 Assessment of infarct size by biomarker measurement.
Assessment of infarct size by biomarker measurement. Serum creatine kinase (CK) release over the first 72 h of reperfusion. Area under the curve (AUC; arbitrary units) of serum CK release was measured in control (black) and postconditioned (grey) patients. There was a significant 19% reduction in the AUC of CK release for postconditioned versus control (p=0.027). Sophie Pichot et al. Open Heart 2015;2:e000175 ©2015 by British Cardiovascular Society

Download ppt "Assessment of infarct size by biomarker measurement."

Similar presentations

Comparison between Kaplan-Meier survival estimates of Bristol aortic valve surgery patients and the Monte Carlo-based generated Kaplan-Meier curve using.

Comparison between Kaplan-Meier survival estimates of Bristol aortic valve surgery patients and the Monte Carlo-based generated Kaplan-Meier curve using.
Kaplan-Meier survival curves comparing survival between both time periods according to management strategy. Survival in patients with infective endocarditis.

Kaplan-Meier survival curves comparing survival between both time periods according to management strategy. Survival in patients with infective endocarditis.
Death, target vessel revascularisation (TVR) and myocardial infarction (MI) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES)

Death, target vessel revascularisation (TVR) and myocardial infarction (MI) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES)
P2Y12 blockade versus placebo; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

P2Y12 blockade versus placebo; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.
Receiver operating curves (ROC) of the Framingham and QRISK2 risk factor models for predicting 10-year risk of cardiovascular disease with and without.

Receiver operating curves (ROC) of the Framingham and QRISK2 risk factor models for predicting 10-year risk of cardiovascular disease with and without.
Forest plot of risk ratio with its 95% CI for the incidence of contrast-induced nephropathy among patient taking statin versus control based on renal impairment.

Forest plot of risk ratio with its 95% CI for the incidence of contrast-induced nephropathy among patient taking statin versus control based on renal impairment.
Flow chart of the study population according to thienopyridines used in the FAST-MI registry in patients with STEMI and NSTEMI. FAST-MI, French Registry.

Flow chart of the study population according to thienopyridines used in the FAST-MI registry in patients with STEMI and NSTEMI. FAST-MI, French Registry.
Masashi Maeda et al. Heart Asia 2013;5:7-14

Masashi Maeda et al. Heart Asia 2013;5:7-14
Patients’ preferences do not always match maximisation of lifespan.

Patients’ preferences do not always match maximisation of lifespan.
(A) Illustration of the receiver operating characteristic (ROC) curve (discrimination) of the recalibrated model on the external validation set data. (A)

(A) Illustration of the receiver operating characteristic (ROC) curve (discrimination) of the recalibrated model on the external validation set data. (A)
Endothelial function at baseline and follow-up (responders in white bars and non-responders in black). Endothelial function at baseline and follow-up (responders.

Endothelial function at baseline and follow-up (responders in white bars and non-responders in black). Endothelial function at baseline and follow-up (responders.
HOMA calculations where glucose is mmol/L and insulin is mU/L

HOMA calculations where glucose is mmol/L and insulin is mU/L
(A) Kaplan-Meier curve showing AF-free survival after a single procedure for patients grouped according to use of CT integration. (A) Kaplan-Meier curve.

(A) Kaplan-Meier curve showing AF-free survival after a single procedure for patients grouped according to use of CT integration. (A) Kaplan-Meier curve.
(A) Safety outcome: risk of major bleeding between triple antiplatelet therapy (TAPT) versus dual antiplatelet therapy (DAPT). (A) Safety outcome: risk.

(A) Safety outcome: risk of major bleeding between triple antiplatelet therapy (TAPT) versus dual antiplatelet therapy (DAPT). (A) Safety outcome: risk.
Flow chart of the Jakarta Cardiovascular Care Unit (CCU) Network System. Flow chart of the Jakarta Cardiovascular Care Unit (CCU) Network System. There.

Flow chart of the Jakarta Cardiovascular Care Unit (CCU) Network System. Flow chart of the Jakarta Cardiovascular Care Unit (CCU) Network System. There.
(A) Meta-analysis of repeat revascularisation in randomised trials.

(A) Meta-analysis of repeat revascularisation in randomised trials.
Death, target vessel revascularisation (TVR) and myocardial infarction (MI) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES)

Death, target vessel revascularisation (TVR) and myocardial infarction (MI) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES)
Comparison of CMR and echocardiography in aortic regurgitation.

Comparison of CMR and echocardiography in aortic regurgitation.
Receiver operating characteristic curves for the association of primary outcome using each clinical risk score and each clinical risk score adjusted for.

Receiver operating characteristic curves for the association of primary outcome using each clinical risk score and each clinical risk score adjusted for.
(A) Primary cardiovascular outcome: risk of major adverse cardiovascular effects (MACE) between triple antiplatelet therapy (TAPT) versus dual antiplatelet.

(A) Primary cardiovascular outcome: risk of major adverse cardiovascular effects (MACE) between triple antiplatelet therapy (TAPT) versus dual antiplatelet.

Similar presentations

Ads by Google